# Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

> **NCT03440424** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Lemborexant

## Key facts

- **NCT ID:** NCT03440424
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-26
- **Primary completion:** 2018-04-23
- **Final completion:** 2018-04-23
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03440424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03440424, "Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03440424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*